The Role of Statins in Prevention and Treatment of Community Acquired Pneumonia: A Systematic Review and Meta-Analysis

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Khan, Abdur Rahman ^a   Riaz, Muhammad ^b   Abdulhak, Aref A Bin ^c   Al Tannir, Mohamad A ^b   Garbati, Musa A ^b   Erwin, Patricia J ^d   Baddour, Larry M ^d   Tleyjeh, Imad M ^b,d,e  

^a UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

^b KING FAHAD MEDICAL CITY   (Saudi Arabia)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

^e ALFAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CASE CONTROL STUDY; CLINICAL EVALUATION; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; HUMAN; INFECTION RISK; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

COMMUNITY-ACQUIRED INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PNEUMONIA;

SCOPUS;

EID: 84872253001     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052929     Document Type: Review

References (67)

1. Torres A, Rello J (2010) Update in Community-acquired and Nosocomial Pneumonia 2009. AJRCCM. 181: 782-787. [PMID: 20382801].
2. Chiou CC, Yu LV (2006) Severe pneumococcal pneumonia: new strategies for management. Curr Opin Crit Care. 12: 470-6. [PMID:16943728].
3. Mortensen EM, Coley CM, Singer DE, Marrie TJ, Obrosky DS, et al. (2002) Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med. 162: 1059-1064. [PMID: 11996618].
4. Mortensen EM, Kapoor WN, Chang CC, et al. (2003) Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. Clin Infect Dis. 37: 1617-1624. [PMID: 14689342].
5. Waterer GW, Kessler LA, Wunderink RG, (2004) Medium-term survival after hospitalization with community-acquired pneumonia. Am J Respir Crit Care Med. 169: 910-914.
6. Kung HC, Hoyert DL, Xu J, Murphy SL, (2008) Deaths: final data for 2005. Natl Vital Stat Rep. 56(10): 1-124.
7. Wang H, Ma S (2008) The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. American Journal of Emergency Medicine. 26: 711-715. [PMID:18606328].
8. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, et al. (2007) Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) study. Arch Intern Med. 167(15): 1655-1663. [PMID: 17698689].
9. Menéndez R, Cavalcanti M, Reyes S, Mensa J, Martinez R, et al. (2008) Markers of treatment failure in hospitalised community acquired pneumonia. Thorax. 63(5): 447-52. [PMID: 18245147].
10. Fernandez-Serrano S, Dorca J, Coromines M, Carratalà J, Gudiol F, et al. (2003) Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol. 10: 813-820 [PIMD: 12965910].
11. Antunes G, Evans SA, Lordan JL, Frew AJ (2002) Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J. 20: 990-995. [PMID: 12412694].
12. Kwak B, Mulhaupt F, Myit S, Mach F (2000) Statins as a newly recognized type of immunomodulator. Nat Med. 6(12): 1399-1402. [PMID:11100127].
13. Steiner S, Speid WS, Pleiner J, Seidinger D, Zorn G, et al. (2005) Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation. 111(14): 1841-1846. [PMID:15824212].
14. Catron DM, Lange Y, Borensztajn J, Sylvester MD, Jones BD, et al. (2004) Salmonella enterica serovar Typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway for intracellular proliferation. Infect Immun. 72(2): 1036-1042. [PMID:14742551].
15. Danesh J, Collins R, Appleby P, Peto R (1998) Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 279: 1477-82. [PMID:9600484].
16. Mendall MA, Patel P, Asante M, Ballam L, Morris J, et al. (1997) Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart. 78(3): 273-7. [PMID:9391290].
17. Kumar A, Thota V, Dee L, Olson J, Uretz E, et al. (1996) Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med. 183: 949-58. [PMID: 8642298].
18. Mann DL (2002) Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 91: 988-98. [PMID: 12456484].
19. Ramirez J, Aliberti S, Mirsaeidi M, Peyrani P, Filardo G, et al. (2008) Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis. 47(2): 182-187. [PMID: 18533841].
20. Shin WS, Szuba A, Rockson SG (2002) The role of chemokines in human cardiovascular pathology: enhance bioloical insights. Atherosclerosis. 160(1): 91-102. [PMID: 11755926].
21. Corrales-Medina VF, Madjid M, Musher DM, (2010) Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis. 10: 83-92.
22. Musher DM, Rueda AM, Kaka AS, Mapara SM (2007) The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 45(2): 158-65. [PMID: 17578773].
23. Perry TW, Pugh MJ, Waterer GW, Nakashima B, Orihuela CJ, et al. (2011) Incidence of cardiovascular events after hospital admission for pneumonia. Am J Med. 124(3): 244-51. [PMID: 21396508].
24. Corrales-Medina VF, Serpa J, Rueda AM, Giordano TP, Bozkurt B, et al. (2009) Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes. Medicine (Baltimore). 88(3): 154-159 [PMID:19440118].
25. Yende S, D'Angelo G, Mayr F, Kellum JA, Weissfeld S, et al. (2011) Elevated hemostasis markers after pneumonia increases one-year risk of all cause and cardiovascular deaths. PloS ONE. 6(8): e22847. [PMID:21853050].
26. Serhan CN, Chiang N, Van Dyke TE (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8: 349-361. [PMID: 18437155].
27. Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, et al. (2009) Statins for the Prevention and Treatment of Infections. A Systematic Review and Meta-analysis. Arch Intern Med. 169(18): 1658-1667. [PMID:19822822].
28. Janda S, Young A, FitzGerald JM, Etminan M, Swiston J (2010) The effect of statins on mortality from severe infections and sepsis: A systematic review and meta-analysis. J Crit Care. 25(4): 656.e7-22. [PMID: 20413251].
29. Bjorkhem-Bergman L, Bergman P, Andersson J, Lindh JD (2010) Statin Treatment and Mortality in Bacterial Infections - A Systematic Review and Meta-Analysis. PLoS ONE. 19;5(5):e1070. [PMID: 20502712].
30. Dublin S, Jackson ML, Nelson JC, Weiss NS, Larson EB, et al. (2009) Jackson LA. Statin use and risk of community acquired pneumonia in older people: population based case-control study. BMJ. 338: b2137. [PMID: 19531550].
31. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S (2009) Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol. 67(1): 99-109. [PMID: 19006546].
32. Fleming DM, Verlander NQ, Elliot AJ, Zhao H, Gelb D, et al. (2010) An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998-1999 to 2005-2006. Epidemiol Infect. 138: 1281-1288. [PMID: 20109259].
33. Myles PR, Hubbard RB, McKeever TM, Z Pogson, Smith CJP, et al. (2009) Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiology and drug safety. 18: 269-275.
34. Van de Garde EMW, Hak E, Souverein PC, Hoes AW, van den Bosch JMM, et al. (2006) Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax. 61: 957-961. [PMID: 16809409].
35. Vinogradova Y, Coupland C, Hippisley-Cox J (2011) Risk of pneumonia in patients taking statins: population-based nested case-control study. Br J Gen Pr. 61(592): e742-8 [PMID: 220543381].
36. Schlienger RG, Fedson DS, Jick SS, Jick H, Meier CR (2007) Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy. 27: 325-32. [PMID: 17316144]
37. Kwong JC, Li P, Redelmeier DA (2009) Influenza Morbidity and Mortality in Elderly Patients Receiving Statins: A Cohort Study. PLoS ONE. 4(11): e8087. [PMID: 19956645]
38. Frost FJ, Petersen H, Tollestrup K, Skipper B (2007) Influenza and COPD Mortality Protection as Pleiotropic, Dose-Dependent Effects of Statins. Chest. 131: 1006-1012. [PMID: 17426203].
39. Mortensen EM, Pugh MJ, Copeland LA, Restrepo MI, Cornell JE,et al. 92008) Impact of statins and angiotensin converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J. 31: 611-617. [PMID: 17959631].
40. Mortensen EM, Restrepo MI, Anzueto A, Pugh J (2005) The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respiratory Research. 6: 82 [PMID: 16042797].
41. Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, et al. (2008) Preadmission Use of Statins and Outcomes After Hospitalization With Pneumonia. Arch Intern Med. 168(19): 2081-2087. [PMID: PMID:18955636].
42. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ (2006) Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ. 11; 333(7576): 999. [PMID: 17060337].
43. Chalmers JD, Singanayagam A, Murray MP, Hill AT (2008) Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med. 121: 1002-1007. [PMID:18954848].
44. Myles PR, Hubbard RB, Gibson JE, Pogson Z. Smith CJP, et al. (2009) The impact of statins, ACE inhibitors and gastric acid suppressants on pneumonia mortality in a UK general practice population cohort. Pharmacoepidemiology and drug safety. 18: 697-703. [PMID:19455553].
45. Douglas I, Evans S, Smeeth L (2011) Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ. 342: d1642. [PMID: 21471172].
46. Yende S, Milbrandt EB, Kellum JA, Kong L, Delude RL, et al. (2011) Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med. 39(8): 1871-8. [PMID: 21516038].
47. Rothberg MB, Bigelow C, Pekow PS, Lindenauer PK (2011) Association Between Statins Given in Hospital and Mortality in Pneumonia Patients. J Gen Intern Med. [Epub ahead of print] [PMID: 21842322].
48. Kwok CS, Yeong JK, Turner RM, Cavallazzi R, Singh S, et al. (2012) Statins and associated risk of pneumonia: a systematic review and meta-analysis of observational studies. Eur J Clin Pharmacol. 68(5): 747-55. Epub 2011 Nov 15.
49. Chopra V, Rogers MA, Buist M, Govindan S, Lindenauer PK, et al. (2012)Is Statin Use Associated with Reduced Mortality After Pneumonia? A Systematic Review and Meta-analysis Am J Med. [Epub ahead of print].
50. Van den Hoek HL, Bos WJ, de Boer A, van de Garde EM (2011) Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials BMJ. 29; 343: d7281. [PMID: 22127443].
51. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, et al. (2008) Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1 [updated September 2008]. The Cochrane Collaboration. Available: www.cochrane-handbook.org.
52. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of obser vational studies in epidemiology (MOOSE) group. JAMA. 19;283(15): 2008-12. [PMID: 10789670].
53. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 339: b2700. [PMID: 19622552].
54. Taddio A, Pain T, Fassos FF, Boon H, Ilersic AL, et al. (1994) Quality of nonstructured and structured abstracts of original research articles in the British medical journal, the Canadian medical association journal and the journal of the American medical association. CMAJ. 150(10): 1611-1615 [PMID: 8174031].
55. Scherer RW, Langenberg P and von Elm E (2007) Full publication of results initially presented in abstracts. Cochrane Database of Systematic Reviews. 18; (2): MR000005. [PMID: 17443628].
56. Wells G, Shea B, O'Connell D, J Peterson, V Welch, et al. (2011) The Newcastle- Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Ottawa, Ontario: The Ottawa Health Research Institute. Available: http://www.ohri.ca/programs/clinicalepidemiology/nosgen.doc. Accessed 2011 Sept 13.
57. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials. 7(3): 177-188.
58. Higgins JP, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med. 21(11): 1539-1558.
59. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L, (2008) Contour-enhanced meta-analysis funnel plots help distinguishing publications bias from other causes of asymmetry. J Clin Epidemiol. 61: 991-996.
60. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ. 315(7109): 629-634.
61. Moreno SG, Sutton AJ, Ades AE, Stanley TD, Abrams KR, et al. (2009) Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study. BMC Med Res Methodol. 9: 2. [PMID: 19138428].
62. Duval S, Tweedie R, (2000) A Nonparametric "Trim and Fill" Method of Accounting for Publication Bias in Meta-Analysis. Journal of the American Statistical Association. 95(449): 89-98.
63. Schneeweiss S (2006) Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 15(5): 291-303. [PMID:16447304].
64. Zhang J, Yu KF (1998) What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 18;280(19): 1690-1. [PMID: 9832001].
65. Impact of Statins on Cytokine Expression in Pneumonia. Available: http://clinicaltrials.gov/ct2/show/NCT00946166?term=pneumonia%2Cstatins &rank=1. 2012 Jun 11.
66. Makris D, Manoulakas E, Komnos A, Papakrivou E, Tzovaras N, et al. (2011) Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: open label, randomized study. Crit Care Med. 39(11): 2440-6. [PMID 21725239].
67. Glynn RJ, Schneeweiss S, Wang PS, Levin R, Avorn J (2006) Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol. 59: 819-28. [PMID:16828675].